Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped down before the market opened on Monday . The stock had previously closed at $27.68, but opened at $26.19. Ascentage Pharma Group International shares last traded at $26.12, with a volume of 984 shares trading hands.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research report on Monday, November 24th. BTIG Research started coverage on Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.50.

Ascentage Pharma Group International Trading Down 6.8%

The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The business has a 50 day simple moving average of $31.64 and a 200 day simple moving average of $36.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of the business. Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International in the second quarter valued at approximately $227,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth $391,000. Tema Etfs LLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth $610,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth about $96,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.